New combo therapy aims to shrink kidney tumors before surgery

NCT ID NCT07172386

Recruiting now Disease control Sponsor: Tianjin Medical University Second Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 trial tests a three-part approach for advanced kidney cancer: first, a procedure to block blood flow to the tumor, then two drugs (toripalimab and axitinib) before surgery, followed by more toripalimab after surgery. The goal is to see if this makes surgery more successful and controls the cancer longer. The study involves 40 participants and is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: toripalimab and axitinib
What this could lead to: If successful, this combination could improve surgical outcomes and control advanced kidney cancer more effectively, potentially extending survival.
What could go wrong: This is a small, early-phase trial with only 40 participants. The treatment may cause side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA (RCC)

Contacts and locations

Locations

Tianjin Medical University Second Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300211, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.